v3.26.1
Revenue- Gilead Science Inc (Details)
1 Months Ended 3 Months Ended 6 Months Ended
Nov. 30, 2025
USD ($)
performanceObligation
Jun. 30, 2024
USD ($)
Oct. 31, 2022
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Sep. 30, 2023
USD ($)
Collaboration And Other Agreements [Line Items]                  
Total revenues       $ 32,832,000 $ 6,869,000 $ 39,553,000 $ 13,911,000    
Deferred revenue, current       55,503,000   55,503,000   $ 1,276,000  
Deferred revenue, net of current portion       0   0   55,503,000  
Gilead | 2022 Gilead Collaboration And License Agreement                  
Collaboration And Other Agreements [Line Items]                  
Non-refundable upfront payment     $ 60,000,000            
Total revenues       1,000,000 500,000 1,300,000 100,000    
Deferred revenue               56,800,000  
Deferred revenue, current       $ 55,500,000   $ 55,500,000   1,300,000  
Deferred revenue, net of current portion               $ 55,500,000  
Potential target nomination, option fees and milestone payments     $ 1,700,000,000            
Gilead | Gilead First Research Program                  
Collaboration And Other Agreements [Line Items]                  
Total revenues   $ 3,300,000     $ 5,600,000   $ 11,000,000    
Revenue, remaining performance obligation, amount                 $ 15,700,000
Potential option fee                 $ 10,000,000
Gilead | Gilead Second Research Program                  
Collaboration And Other Agreements [Line Items]                  
Non-refundable upfront payment $ 25,000,000                
Number of performance obligations | performanceObligation 1